The branding is clean, the product imagery looks medical-grade, and the website often includes clinical buzzwords like transdermal GLP-1 activation, fat metabolism modulation, or nanotechnology diffusion. These phrases sound convincing but theyre designed to manipulate, not inform
DPP-4 was first identified as CD26, and is a 110 kD protein that can be found on the cell surface as a monomer, homodimer, or homotetramer
The many distribution channels that guarantee the medication reaches consumers and healthcare providers efficiently have a major impact on this market segment
1,6 While specific data vary by product and region, the general expectation is: Mid-2020s - early 2030s: foundational peptide patents expire Late 2020s - mid-2030s: formulation and device patents phase out Ongoing regulatory exclusivities (e.g., data exclusivity) may further delay competition
David: And it's moving slower